DUL:F:F-Alnylam Pharmaceuticals Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 252.2

Change

-3.40 (-1.33)%

Market Cap

USD 35.18B

Volume

10.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
CSJA:F CSL LTD SPON.ADR 2

+0.50 (+0.73%)

USD 67.81B
CSJ:F CSL Limited

-1.00 (-0.72%)

USD 67.05B
RGO:F Regeneron Pharmaceuticals Inc

-20.40 (-3.80%)

USD 58.84B
1AEA:F argenx SE

-5.00 (-0.98%)

USD 36.54B
1AE:F Argen-X

+1.80 (+0.35%)

USD 34.68B
UNC0:F UCB S.A. UNSP.ADR 1/2

-1.00 (-1.25%)

USD 27.89B
49B:F BeiGene Ltd.

+0.26 (+1.62%)

USD 26.89B
49BA:F BeiGene Ltd

N/A

USD 25.20B
22UA:F BioNTech SE

-2.10 (-2.36%)

USD 21.41B
RPD:F ROYALTY PHARMA OA DL-0001

-0.78 (-2.69%)

USD 16.36B

ETFs Containing DUL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.69% 74% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.69% 74% C 74% C
Trailing 12 Months  
Capital Gain 83.89% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.89% 90% A- 89% A-
Trailing 5 Years  
Capital Gain 98.43% 91% A- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 98.43% 89% A- 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 21.37% 78% C+ 83% B
Dividend Return 21.37% 77% C+ 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.88% 66% D+ 45% F
Risk Adjusted Return 69.18% 94% A 77% C+
Market Capitalization 35.18B 99% N/A 94% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.